Market Overview:
The global proton pump inhibitor drug market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of gastrointestinal disorders, rising geriatric population, and growing demand for proton pump inhibitors drugs in emerging markets. Based on type, the global proton pump inhibitor drug market is segmented into omeprazole, lansoprazole, pantoprazole, rabeprazole and others. Omeprazole is currently the most popular proton pump inhibitor drug and accounts for a major share of this market. Based on application, the global proton pump inhibitor drug market is segmented into hospital pharmacies, retail pharmacies and laboratories. The hospital pharmacies segment dominates this market owing to high demand for these drugs in hospitals for treating various gastrointestinal disorders such as peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome (ZES).
Product Definition:
A proton pump inhibitor (PPI) is a type of drug that blocks the production of stomach acid. PPIs are used to treat conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger-Ellison syndrome.
Omeprazole:
Omeprazole is an anti-gastric drug which works by inhibiting the acid production in the stomach. Omeprazole is used to treat ulcers and peptic ulcers, and to reduce reflux of various drugs including histamine, amiodarone, phenytoin sodium and warfarin. It also has uses as a prophylactic against heartburn after meals.
Lansoprazole:
Lansoprazole is a proton pump inhibitor (PPI) drug developed by GlaxoSmithKline. It was first approved in the U.S. as part of the generic line of drugs called “Zantac” in 1994, and later re-branded under the name “Ranexa” in 2002, by GlaxoSmithKline Pharmaceuticals Limited.
Application Insights:
Proton pump inhibitors are used for the treatment of various diseases, including gastric and duodenal ulcers, Zollinger-Ellison syndrome, acid reflux disease (GERD), and heartburn. The hospital segment dominated the global market in 2017 owing to a large number of prescriptions written for Helicobacter pylori infection and other conditions related to stomach cancer.
The others application segment includes conditions such as osteoporosis and arthritis. Owing to increasing incidences of osteoarthritis worldwide, demand from this segment is anticipated to grow over the forecast period. Rabeprazole is one of the most prescribed drugs for treating gastritis due largely in part its high efficacy against H pylori infections coupled with fewer side effects compared to other proton pump inhibitors available in the market such as omeprazole and pantoprazole.
Rabeprazole has been approved by U.
Regional Analysis:
Asia Pacific is expected to be the fastest-growing regional market with a CAGR of XX% over the forecast period. The presence of key players in countries, such as Japan and China, has led to an increase in availability and accessibility of proton pump inhibitors in this region. Moreover, increasing healthcare expenditure coupled with rising prevalence of lifestyle-associated diseases is anticipated to drive growth during the forecast period.
North America was estimated as the second-largest regional market for proton pump inhibitor drugs after Europe in 2017 due to high consumption rates and favorable reimbursement policies pertaining hospitalization costs associated with LESION formation or treatment procedures leading to gastric cancer diagnosis or treatment expenses under Medicare Part A & B coverage which are major factors driving demand for PPIs drugs used for treating these conditions resulting from stomach cancer surgery complications at hospitals outpatient settings across U.S.
Growth Factors:
- Increasing incidence of gastrointestinal diseases: The incidence of gastrointestinal diseases is increasing globally, which is expected to drive the demand for proton pump inhibitors in the coming years.
- Growing awareness about proton pump inhibitors: There is a growing awareness among people about the benefits of proton pump inhibitors, which is likely to boost the market growth in the near future.
- Rising number of geriatric population: The number of geriatric population is increasing globally, which will lead to an increase in demand for proton pump inhibitor drugs over the forecast period.
- Technological advancements: Proton pump inhibitor drugs are witnessing technological advancements with newer and more effective products being launched in the market, thereby driving their growth prospects over the forecast period. 5) Increase in healthcare expenditure: There has been a rise in global healthcare expenditure due to rising income levels and this is anticipated to fuel demand for proton pump inhibitor drugs duringthe forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Proton Pump Inhibitor Drug Market Research Report
By Type
Omeprazole, Lansoprazole, Pantoprazole, Rabeprazole, Others
By Application
Hospital, Laboratory, Others
By Companies
AstraZeneca, Cadila Pharmaceuticals, Eisai, Eli Lilly, Janssen, Pfizer, Santarus, Wyeth
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Proton Pump Inhibitor Drug Market Report Segments:
The global Proton Pump Inhibitor Drug market is segmented on the basis of:
Types
Omeprazole, Lansoprazole, Pantoprazole, Rabeprazole, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Laboratory, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Cadila Pharmaceuticals
- Eisai
- Eli Lilly
- Janssen
- Pfizer
- Santarus
- Wyeth
Highlights of The Proton Pump Inhibitor Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Omeprazole
- Lansoprazole
- Pantoprazole
- Rabeprazole
- Others
- By Application:
- Hospital
- Laboratory
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Proton Pump Inhibitor Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A proton pump inhibitor drug is a medication that blocks the action of the proton pump, an enzyme responsible for breaking down fats in the intestines. This can lead to decreased absorption of fat-soluble vitamins and minerals from food, which can increase your risk for developing chronic diseases such as heart disease, stroke, and some types of cancer.
Some of the major players in the proton pump inhibitor drug market are AstraZeneca, Cadila Pharmaceuticals, Eisai, Eli Lilly, Janssen, Pfizer, Santarus, Wyeth.
The proton pump inhibitor drug market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Proton Pump Inhibitor Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Proton Pump Inhibitor Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Proton Pump Inhibitor Drug Market - Supply Chain
4.5. Global Proton Pump Inhibitor Drug Market Forecast
4.5.1. Proton Pump Inhibitor Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Proton Pump Inhibitor Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Proton Pump Inhibitor Drug Market Absolute $ Opportunity
5. Global Proton Pump Inhibitor Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Proton Pump Inhibitor Drug Market Size and Volume Forecast by Type
5.3.1. Omeprazole
5.3.2. Lansoprazole
5.3.3. Pantoprazole
5.3.4. Rabeprazole
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Proton Pump Inhibitor Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Proton Pump Inhibitor Drug Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Laboratory
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Proton Pump Inhibitor Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Proton Pump Inhibitor Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Proton Pump Inhibitor Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Proton Pump Inhibitor Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Proton Pump Inhibitor Drug Demand Share Forecast, 2019-2026
9. North America Proton Pump Inhibitor Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Proton Pump Inhibitor Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Proton Pump Inhibitor Drug Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Laboratory
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Proton Pump Inhibitor Drug Market Size and Volume Forecast by Type
9.7.1. Omeprazole
9.7.2. Lansoprazole
9.7.3. Pantoprazole
9.7.4. Rabeprazole
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Proton Pump Inhibitor Drug Demand Share Forecast, 2019-2026
10. Latin America Proton Pump Inhibitor Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Proton Pump Inhibitor Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Proton Pump Inhibitor Drug Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Laboratory
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Proton Pump Inhibitor Drug Market Size and Volume Forecast by Type
10.7.1. Omeprazole
10.7.2. Lansoprazole
10.7.3. Pantoprazole
10.7.4. Rabeprazole
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Proton Pump Inhibitor Drug Demand Share Forecast, 2019-2026
11. Europe Proton Pump Inhibitor Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Proton Pump Inhibitor Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Proton Pump Inhibitor Drug Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Laboratory
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Proton Pump Inhibitor Drug Market Size and Volume Forecast by Type
11.7.1. Omeprazole
11.7.2. Lansoprazole
11.7.3. Pantoprazole
11.7.4. Rabeprazole
1.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Proton Pump Inhibitor Drug Demand Share, 2019-2026
12. Asia Pacific Proton Pump Inhibitor Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Proton Pump Inhibitor Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Proton Pump Inhibitor Drug Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Laboratory
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Proton Pump Inhibitor Drug Market Size and Volume Forecast by Type
12.7.1. Omeprazole
12.7.2. Lansoprazole
12.7.3. Pantoprazole
12.7.4. Rabeprazole
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Proton Pump Inhibitor Drug Demand Share, 2019-2026
13. Middle East & Africa Proton Pump Inhibitor Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Proton Pump Inhibitor Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Proton Pump Inhibitor Drug Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Laboratory
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Proton Pump Inhibitor Drug Market Size and Volume Forecast by Type
13.7.1. Omeprazole
13.7.2. Lansoprazole
13.7.3. Pantoprazole
13.7.4. Rabeprazole
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Proton Pump Inhibitor Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Proton Pump Inhibitor Drug Market: Market Share Analysis
14.2. Proton Pump Inhibitor Drug Distributors and Customers
14.3. Proton Pump Inhibitor Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AstraZeneca
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Cadila Pharmaceuticals
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Eisai
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Eli Lilly
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Janssen
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Pfizer
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Santarus
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Wyeth
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
